BRIEF published on 09/18/2024 at 07:05, 2 years 1 month ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 2 years 1 month ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 2 years 2 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 2 years 2 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 2 years 2 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 2 years 2 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 2 years 3 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 2 years 3 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 2 years 4 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 2 years 4 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 11/06/2026 at 00:45, 14 minutes ago Gabriel Announces Closure of ICSID Annulment Proceedings
Published on 11/05/2026 at 23:20, 1 hour 39 minutes ago Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Published on 11/05/2026 at 22:05, 2 hours 54 minutes ago Innodata Reports Record Third Quarter 2026 Results
Published on 11/05/2026 at 22:01, 2 hours 58 minutes ago Unusual Machines Third Quarter 2026 Shareholder Letter
Published on 11/05/2026 at 15:20, 9 hours 39 minutes ago MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors
Published on 11/06/2026 at 00:05, 54 minutes ago RBI: Announcement of the result of the voluntary public tender offer for all Addiko shares following expiration of the grace period
Published on 11/05/2026 at 22:05, 2 hours 54 minutes ago Quantinuum Reports Third Quarter 2026 Results and Raises Full-Year Revenue Outlook
Published on 11/05/2026 at 20:38, 4 hours 21 minutes ago freenet uses funds from Ceconomy sale for waipu.tv acquisition and share buyback
Published on 11/05/2026 at 20:37, 4 hours 22 minutes ago EQS-Adhoc: freenet AG decides on share buyback programme for up to EUR 75 million
Published on 11/05/2026 at 19:45, 5 hours 13 minutes ago Stabilus SE fulfills forecast for fiscal 2026 and adjusts 2030 medium-term targets
Published on 11/05/2026 at 18:21, 6 hours 37 minutes ago Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:45, 7 hours 14 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 7 hours 30 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
Published on 11/05/2026 at 10:16, 14 hours 43 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
